Title |
Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
|
---|---|
Published in |
Clinical and Molecular Allergy, March 2020
|
DOI | 10.1186/s12948-020-00119-4 |
Pubmed ID | |
Authors |
Rachel Husmann, John B. Davies, Malik Ghannam, Brent Berry, Praful Kelkar |
Abstract |
Fingolimod, an immunomodulatory agent, is used for the treatment of relapsing-remitting multiple sclerosis (RRMS). Fingolimod-associated macular edema (FAME) is a known complication with an incidence of 0.4%. The current recommendation for treatment of FAME is cessation of fingolimod. There are few case reports with management of FAME with steroid eye drops. A 38-year-old Caucasian female patient with history of relapsing-remitting multiple sclerosis (RRMS) and treated with fingolimod developed Fingolimod-associated macular edema (FAME). Nevertheless, FAME was successfully treated with nonsteroidal anti-inflammatory eye drops without discontinuation of fingolimod. FAME may be managed with non-steroidal eye drops without discontinuation of fingolimod in appropriate patient monitored with close follow up. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 17 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Doctoral Student | 4 | 24% |
Student > Bachelor | 3 | 18% |
Student > Master | 3 | 18% |
Student > Ph. D. Student | 1 | 6% |
Student > Postgraduate | 1 | 6% |
Other | 0 | 0% |
Unknown | 5 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 41% |
Nursing and Health Professions | 3 | 18% |
Neuroscience | 1 | 6% |
Unknown | 6 | 35% |